Organon Expands Further with the Acquisition of MSD Biotech Site in the Netherlands
The leading women’s health company will continue to provide high-quality fertility products to patients worldwide
Joost van Zutven, European Quality Lead Large Molecules MSD Animal Health and Wenny Raaijmakers, Manufacturing Site Leader Organon Oss
Organon, a leading women’s healthcare company, has acquired the MSD Biotech production site in Oss, the Netherlands. The formal handover ceremony took place recently, attended by key local dignitaries and representatives from MSD and Organon.
Following the agreement that was announced last year, the acquisition will see 278 MSD employees transfer to Organon, further expanding the company’s long-established presence in Oss. It includes all fertility activities and associated support roles. The drug substances for two of the company’s fertility products are manufactured at the Biotech Oss site. This investment will ensure Organon can continue to provide high-quality fertility pharmaceuticals to patients worldwide.
Delivering healthcare solutions for women
Wenny Raaijmakers, Plant Manager of Organon in Oss, stated, “Organon is proud of its legacy in Oss and the expertise of its over 1,200 strong existing team in the area. The company is excited to expand its footprint and team in Oss. Organon looks forward to its existing site in Oss continuing to play an important role in its future as it builds and grows its position as a leading women’s healthcare company.”
Raaijmakers continued, “Our fertility franchise is a key area for Organon and the many patients who rely on our treatments. Today marks an important step forward in supporting continued, quality manufacturing, and supply of these medicines for our patients as well as securing jobs in the region and strengthening our capability in this crucial area. We are happy to welcome our new colleagues to Organon and we know that their knowledge and expertise will be invaluable as we expand our fertility business. We look forward to learning, sharing, and collaborating with our new team members to further support our important vision and mission.”
Innovation in the Dutch life sciences & health ecosystem
Organon started as an independent company in Oss in 1923 and was hived off from the American company Merck & Co (MSD) in 2021. In April 2022, Organon announced that it would significantly expand production in the Netherlands. In the following years, Organon has further expanded its healthcare solutions as part of the Dutch life sciences & health ecosystem. In 2023, Organon marked its 100th year of innovating healthcare in the Netherlands with a new Experience Center in Oss, offering a unique insight into the pharmaceutical company which is known for the contraceptive pill and its contribution to women’s health around the world.
About Organon
As an independent healthcare company, Organon is committed to improving the health of women worldwide and to increasing gender and gender-specific healthcare. Organon manufactures more than 60 medicines and other products across a range of areas including reproductive health, heart disease, dermatology, allergies and asthma.
Source: Organon
17 July 2025